144. Lennox-Gastaut syndrome Clinical trials / Disease details
Clinical trials : 101 / Drugs : 68 - (DrugBank : 12) / Drug target genes : 49 - Drug target pathways : 60
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01405053 (ClinicalTrials.gov) | June 16, 2011 | 27/7/2011 | Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs | A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to Less Than 4 Years of Age With Inadequately Controlled Lennox-Gastaut Syndrome | Lennox-Gastaut Syndrome | Drug: Rufinamide;Drug: Any other approved Antiepileptic Drug | Eisai Inc. | NULL | Completed | 1 Year | 3 Years | All | 37 | Phase 3 | United States;Canada;France;Greece;Italy;Poland;South Africa;India |